文献速递衰弱、肌少症与跌倒多重用药老年综合评估

药师减处方干预对衰弱社区老年人抗胆碱能负担影响的事后分析

Post Hoc Analyses of a Randomized Controlled Trial for the Effect of Pharmacist Deprescribing Intervention on the Anticholinergic Burden in Frail Community-Dwelling Older Adults.
PubMed 文献 · J Am Med Dir Assoc · 2023-06-17

该研究为一项在新西兰开展的随机对照减处方试验的事后分析,纳入295名>65岁、基线使用抗胆碱能药物的社区老年人,比较干预组与对照组抗胆碱能认知负担(ACB)变化。结果显示总体干预效应无统计学意义(ĝHedges=-0.04,95%CI -0.26至0.19),干预组ACB平均降低0.23,对照组降低0.19;按封锁前后及衰弱分层未见显著差异。

要点

  • 总体干预对降低ACB无显著效应(ĝHedges=-0.04,95%CI -0.26至0.19)。
  • 干预组ACB平均降低0.23,对照组降低0.19。
  • 封锁前ĝHedges=-0.38(95%CI -0.84至0.04),封锁后0.07(95%CI -0.19至0.33)。

核心结论

  • 该研究未提供药师减处方干预降低抗胆碱能负担的证据。

研究设计与样本

  • 随机对照减处方试验的事后分析,纳入新西兰>65岁社区老年人295名,中位年龄79岁(IQR 74-85),67%为女性。

主要发现

  • 总体ACB变化ĝHedges=-0.04(95%CI -0.26至0.19),干预组平均降低0.23,对照组降低0.19。
  • 封锁前ĝHedges=-0.38(95%CI -0.84至0.04),封锁后ĝHedges=0.07(95%CI -0.19至0.33)。
  • 低衰弱层ACB平均变化-0.02(95%CI -0.65至0.18),中衰弱层0.05(95%CI -0.28至0.38),高衰弱层0.08(95%CI -0.40至0.56)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anticholinergic burden is detrimental to cognitive health. Multiple studies found that a high anticholinergic burden is associated with an increased risk for dementia, changes to the brain structure, function, and cognitive decline. We performed a post hoc analysis of a randomized controlled deprescribing trial. We compared the effect of the intervention on baseline anticholinergic burden across the treatment and control groups and the time of recruitment before and after a lockdown due to the COVID pandemic with subgroup analyses by baseline frailty index. DESIGN: Randomized controlled trial. SETTINGS AND PARTICIPANTS: We analyzed data from a de-prescribing trial of older adults (>65 years) previously conducted in New Zealand that was focused on reducing the Drug Burden Index (DBI). METHODS: We used the anticholinergic cognitive burden (ACB) to quantify the impact of the intervention on reducing the anticholinergic burden. Participants not taking anticholinergics at the start of the trial were excluded. The primary outcome for this subgroup analysis was a change in ACB, measured with the ĝHedges statistic describing the difference in standard deviation units of this change between intervention and control. For this analysis, the trial participants were stratified into low, medium, and high frailty and timing into prior- and post-lockdown (public health measures for COVID-19). RESULTS: Among the 295 participants in this analysis, the median (IQR) age was 79 (74, 85), and 67% were women. For the primary outcome ĝHedges = -0.04 (95% CI -0.26 to 0.19) with a -0.23 mean reduction in ACB in the intervention arm and -0.19 in the control arm. Before lockdown ĝHedges = -0.38 (95% CI -0.84 to 0.04) and post-lockdown ĝHedges = 0.07 (95% CI -0.19 to 0.33). The mean change in ACB for each of the frailty strata was as follows: low frailty (-0.02; 95% CI -0.65 to 0.18); medium frailty (0.05; 95% CI -0.28 to 0.38); high frailty (0.08; 95% CI -0.40 to 0.56). CONCLUSIONS AND IMPLICATIONS: The study did not provide evidence for the effect of pharmacist deprescribing intervention on reducing the anticholinergic burden. However, this post hoc analysis examined the impact of COVID on the effectiveness of the intervention, and further research in this area may be warranted.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Nishtala PS, Pickering JW, Bergler U, et al. Post Hoc Analyses of a Randomized Controlled Trial for the Effect of Pharmacist Deprescribing Intervention on the Anticholinergic Burden in Frail Community-Dwelling Older Adults. J Am Med Dir Assoc. 2023. PMID: 37339754. doi:10.1016/j.jamda.2023.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。